BCG vaccine of 2004 the vaccine is given to about 100 million children per year globally. The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears
Belarusian Railway BCG-1 Belarusian Railway BCG-1 The Belarusian Railways BCG-1, originally Belarusian Railways BKG-1 (БКГ : "Белорусско-Китайский Грузовой"), is a type of twin-unit, eight axle, (Bo'Bo')-(Bo'Bo'), high power mainline electric freight locomotive manufactured by CNR Datong Electric Locomotive for the Belarusian Railway. The locomotives are derived from the China Railways HXD2 locomotive type developed from the Alstom Prima locomotive platform. In April 2010 CNR Datong announced that it had obtained a 700million Yuan contract to supply 12 twin section electric locomotives to Belarus; the locomotives were to be used to increase haulage capacity from the 4700t to 5500t capacity of the 6.52MW VL80S